Publication | Closed Access
Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial
243
Citations
0
References
2009
Year
Surgical OncologyBreast OncologyTumoral PathologyMalignant DiseaseMedicineCancer ManagementPharmacologyPathologyCancer Cell BiologyClinical OncologyBreast CancerMolecular OncologyMay 30Cancer TreatmentOncologyRadiation OncologyCancer ResearchFinal Text
3 The full, final text of this abstract will be available in Part II of the 2009 ASCO Annual Meeting Proceedings, distributed onsite at the Meeting on May 30, 2009, and as a supplement to the June 20, 2009, issue of the Journal of Clinical Oncology. [Table: see text]